Lorenz Mayr, Vector BioPharma CEO (PhoreMost)
Updated: 'Close to the middle': Versant launches Vector with 'gutless adenovirus' delivery method
Most of the gene therapy world centers around viral vectors, but a few biotechs have sprung up in recent years to try and avoid the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
